{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:40:08Z","timestamp":1793947208545,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fluoroquinolone antibiotics have a high potential for serious adverse drug reactions, but real-world evidence in European patient cohorts is lacking. Therefore, we aim to examine the association between fluoroquinolone exposure and potentially life-threatening adverse events stratified by age and gender in Germany.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an administrative cohort study using the active comparator new user design with a risk window up to 365\u00a0days between January 2013 and December 2019. Population-based longitudinal data from one of the largest German statutory health insurances were used. Episodes of newly dispensed fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, and enoxacin) were compared to other antibiotics (amoxicillin, amoxicillin clavulanic acid, azithromycin, cefuroxime, cephalexin, clindamycin, sulfamethoxazole-trimethoprim, and doxycycline). Endpoints were defined by incident diagnoses of aortic aneurysm\/dissection, cardiac arrhythmia, hepatotoxicity, and all-cause mortality. Adjusted hazard ratios were estimated from piece-wise exponential additive mixed models with smooth non-linear effects for person-time and age and adjusted for comorbidities, year and quarter at index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The cohorts comprised 15,139,840; 11,760,159; 11,027,175; and 15,305,757 antibiotic episodes. Patients during fluoroquinolone episodes were older (59 versus 51\u00a0years) and more often female (58% versus 54%). We counted 46,502; 446,727; 19,125; and 474,411 incident endpoints. Relative risk for all-cause mortality and hepatotoxicity was high for\u2009&lt;\u200940-year- and 40\u201369-year-old females (aHR\u2009=\u20091.77, 95% CI 1.55\u20132.03 and aHR\u2009=\u20091.42, 95% CI 1.32\u20131.53), respectively. For aortic aneurysm\/dissection a nominally increased relative risk for\u2009&lt;\u200940-year-old females was found (aHR\u2009=\u20091.42, 95% CI 0.96\u20132.11), although 95% CI indicates that a small relative risk reduction is also supported by the data. Relative risk for cardiac arrhythmia was increased for men aged\u2009&lt;\u200940\u00a0years (aHR\u2009=\u20091.14, 95% CI 1.08\u20131.20). High relative risks for each endpoint were also identified depending on choice of active comparator, and risks increased with higher defined daily doses and shorter follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study contributes real-world evidence to endpoint-specific differences of risks in patient subgroups which need to be considered to improve fluoroquinolone drug safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-025-03919-0","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:08:25Z","timestamp":1738948105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Julia","family":"Wicherski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Peltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Sch\u00fcssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schlotmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried V.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"3919_CR1","unstructured":"European Medicines Agency: Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. In.; 2019. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentiallypermanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf."},{"issue":"9","key":"3919_CR2","doi-asserted-by":"publisher","first-page":"e1800141","DOI":"10.1002\/ardp.201800141","volume":"351","author":"HAA Ezelarab","year":"2018","unstructured":"Ezelarab HAA, Abbas SH, Hassan HA, Abuo-Rahma GEA. Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim). 2018;351(9):e1800141.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"4","key":"3919_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40264-023-01286-4","volume":"46","author":"NF Ly","year":"2023","unstructured":"Ly NF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P, Duarte-Salles T, Reyes C, John LH, Karimi L, et al. Impact of European Union label changes for fluoroquinolone-containing medicinal products for systemic and inhalation use: post-referral prescribing trends. Drug Saf. 2023;46(4):405\u201316.","journal-title":"Drug Saf"},{"issue":"3","key":"3919_CR4","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.ijcard.2013.01.278","volume":"168","author":"B Guzik","year":"2013","unstructured":"Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwa\u0142a M, Bujak-Gizycka B, Filip G, Grudzien G, Kapelak B, Zmudka K, et al. Mechanisms of oxidative stress in human aortic aneurysms\u2013association with clinical risk factors for atherosclerosis and disease severity. Int J Cardiol. 2013;168(3):2389\u201396.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3919_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jtcvs.2018.08.079","volume":"157","author":"DG Guzzardi","year":"2019","unstructured":"Guzzardi DG, Teng G, Kang S, Geeraert PJ, Pattar SS, Svystonyuk DA, Belke DD, Fedak PWM. Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: A potential mechanism of fluoroquinolone-associated aortopathy. J Thorac Cardiovasc Surg. 2019;157(1):109-119.e102.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3919_CR6","doi-asserted-by":"crossref","unstructured":"Adameova A, Shah AK, Dhalla NS: Role of oxidative stress in the genesis of ventricular arrhythmias. Int J Mol Sci. 2020;21(12):4200\u201316.","DOI":"10.3390\/ijms21124200"},{"key":"3919_CR7","doi-asserted-by":"crossref","unstructured":"Negru AG, Pastorcici A, Crisan S, Cismaru G, Popescu FG, Luca CT: the role of hypomagnesemia in cardiac arrhythmias: a clinical perspective. Biomedicines. 2022;10(10):2356-71.","DOI":"10.3390\/biomedicines10102356"},{"issue":"8","key":"3919_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/sj.bjp.0706678","volume":"147","author":"AJ Alexandrou","year":"2006","unstructured":"Alexandrou AJ, Duncan RS, Sullivan A, Hancox JC, Leishman DJ, Witchel HJ, Leaney JL. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol. 2006;147(8):905\u201316.","journal-title":"Br J Pharmacol"},{"key":"3919_CR9","unstructured":"Bundesministerium f\u00fcr Gesundheit (BMG): Gesetzliche Krankenversicherung - Mitglieder, mitversicherte Angeh\u00f6rige und Krankenstand In.; 2024.\u00a0https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlenund-fakten-zur-krankenversicherung\/mitglieder-und-versicherte.html."},{"issue":"21","key":"3919_CR10","first-page":"357","volume":"118","author":"W Gomm","year":"2021","unstructured":"Gomm W, R\u00f6thlein C, Sch\u00fcssel K, Br\u00fcckner G, Schr\u00f6der H, He\u00df S, Fr\u00f6tschl R, Broich K, Haenisch B. N-Nitrosodimethylamine-contaminated valsartan and the risk of cancer\u2014a longitudinal cohort study based on German health insurance data. Dtsch Arztebl Int. 2021;118(21):357\u201362.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"3919_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thom\u00e9 F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410\u20136.","journal-title":"JAMA Neurol"},{"key":"3919_CR12","unstructured":"Gesetzliche Krankenversicherung (GKV) [https:\/\/www.bundesgesundheitsministerium.de\/gkv.html]"},{"key":"3919_CR13","unstructured":"Classifications [https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/_node.html]"},{"issue":"6","key":"3919_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, Dal Pan G, Goettsch W, Murk W, Wang SV. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3919_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"6","key":"3919_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"key":"3919_CR17","unstructured":"Standardbev\u00f6lkerung 2011 [https:\/\/www.gbe-bund.de\/gbe\/isgbe.information?p_uid=gast&p_aid=29865653&p_sprache=D&p_thema_id=7732&p_thema_id2=1&p_thema_id3=&p_thema_id4=]"},{"key":"3919_CR18","unstructured":"Boyle P, Parkin DM: Statistical methods for registries. In: Cancer Registration: Principles and Methods Volume 95, edn. International Agency for Reseach on Cancer (IARC), World Health Organization (WHO): IARC Scientific Publication 1999: 126\u2013158."},{"issue":"3\u20134","key":"3919_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1471082X17748083","volume":"18","author":"A Bender","year":"2018","unstructured":"Bender A, Groll A, Scheipl F. A generalized additive model approach to time-to-event analysis. Stat Model. 2018;18(3\u20134):299\u2013321.","journal-title":"Stat Model"},{"issue":"9","key":"3919_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/phar.2841","volume":"43","author":"M Garg","year":"2023","unstructured":"Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Park H. Oral fluoroquinolones and risk of aortic aneurysm or dissection: a nationwide population-based propensity score-matched cohort study. Pharmacotherapy. 2023;43(9):883\u201393.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"3919_CR21","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/jamainternmed.2020.4199","volume":"180","author":"C Gopalakrishnan","year":"2020","unstructured":"Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180(12):1596\u2013605.","journal-title":"JAMA Intern Med"},{"key":"3919_CR22","doi-asserted-by":"publisher","first-page":"i843","DOI":"10.1136\/bmj.i843","volume":"352","author":"M Inghammar","year":"2016","unstructured":"Inghammar M, Svanstr\u00f6m H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. BMJ. 2016;352:i843.","journal-title":"BMJ"},{"issue":"12","key":"3919_CR23","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/cid\/ciab825","volume":"74","author":"O Nibell","year":"2022","unstructured":"Nibell O, Svanstr\u00f6m H, Inghammar M. Oral fluoroquinolone use and the risk of acute liver injury: a nationwide cohort study. Clin Infect Dis. 2022;74(12):2152\u20138.","journal-title":"Clin Infect Dis"},{"key":"3919_CR24","doi-asserted-by":"publisher","first-page":"k678","DOI":"10.1136\/bmj.k678","volume":"360","author":"B Pasternak","year":"2018","unstructured":"Pasternak B, Inghammar M, Svanstr\u00f6m H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678.","journal-title":"BMJ"},{"issue":"14","key":"3919_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1503\/cmaj.111823","volume":"184","author":"JM Paterson","year":"2012","unstructured":"Paterson JM, Mamdani MM, Manno M, Juurlink DN. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012;184(14):1565\u201370.","journal-title":"CMAJ"},{"issue":"3","key":"3919_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamasurg.2020.6165","volume":"156","author":"ER Newton","year":"2021","unstructured":"Newton ER, Akerman AW, Strassle PD, Kibbe MR. Association of fluoroquinolone use with short-term risk of development of aortic aneurysm. JAMA Surg. 2021;156(3):264\u201372.","journal-title":"JAMA Surg"},{"issue":"6","key":"3919_CR27","doi-asserted-by":"publisher","first-page":"e00664","DOI":"10.1002\/prp2.664","volume":"8","author":"SL Aspinall","year":"2020","unstructured":"Aspinall SL, Sylvain NP, Zhao X, Zhang R, Dong D, Echevarria K, Glassman PA, Goetz MB, Miller DR, Cunningham FE. Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: a self-controlled case series analysis. Pharmacol Res Perspect. 2020;8(6):e00664.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"3919_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciu914","volume":"60","author":"HW Chou","year":"2015","unstructured":"Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and \u03b2-lactam\/\u03b2-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015;60(4):566\u201377.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3919_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1370\/afm.1601","volume":"12","author":"GA Rao","year":"2014","unstructured":"Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, Jacob S, Strayer SM. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12(2):121\u20137.","journal-title":"Ann Fam Med"},{"key":"3919_CR30","doi-asserted-by":"crossref","unstructured":"Debus ES, Heidemann F, Gross-Fengels W, Mahlmann A, Muhl E, Pfister K, Roth S, Stroszczynski C, Walther A, Weiss N et al: S3-Leitlinie zu Screening, Diagnostik, Therapie und Nachsorge des Bauchaortenaneurysmas. In., vol. AWMF-004\u201314; 2018.","DOI":"10.1007\/s00772-018-0435-3"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03919-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:08:37Z","timestamp":1738948117000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03919-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03919-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}